# TG4070

Source: https://onco.cc/drugs/tg4070/  
OnCo record `tg4070` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TG4070 is an experimental individualised neoantigen therapeutic vaccine from Transgene, in phase 1 trials for non-small cell lung cancer.

## Summary

TG4070 is an individualised neoantigen therapeutic vaccine (myvac platform) from Transgene. Transgene's second individualised neoantigen therapeutic vaccine from the myvac platform, given with nivolumab after surgery. Its furthest stage is phase 1, for non-small cell lung cancer (resected, adjuvant). No clinical trial naming it is registered on ClinicalTrials.gov. Transgene: phase 1 in resected NSCLC after neoadjuvant nivolumab plus chemotherapy. No ClinicalTrials.gov record found for TG4070 (query.intr and query.term searched). It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline
- Code: TG4070
- Modality: Individualised neoantigen therapeutic vaccine (myvac platform)
- Mechanism: Transgene's second individualised neoantigen therapeutic vaccine from the myvac platform, given with nivolumab after surgery.

## Sources

- Transgene: transgene.com: https://www.transgene.com/tg4070/

## Connected records

- companies: [Transgene](https://onco.cc/companies/transgene/)

---
JSON: https://onco.cc/api/v1/entities/tg4070.json